Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Collagen-based biodegradable matrices for localized drug delivery More
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
Suite of proprietary collagen-binding peptides derived from bone sialoprotein (BSP) that are effective in promoting bone repair and regeneration. More
Biotechnology Product for Wound Healing More
Identification and use of RAR antagonists to induce bone and cartilage formation More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
This invention relates to a new siRNA-containing organ storage and reperfusion solution for use in transplantation. More
A botanical drug, WH-1, has been approved for US FDA Phase II clinical trials for the treatment of diabetic foot ulcers and also potentially indicated for similar chronic wound healing management conditions. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Accident & Trauma (other)
- Back Pain
- Bone fractures
- Burns
- CNS trauma
- Drug overdose
- Hemorraghic trauma
- Muscle sprain/strain
- Poisioning
- Reperfusion injury (lung/heart)
- Stroke/traumatic brain injury
- Tissue grafting
- Wound closure/surgical adhesive
- Wound/ulcer healing
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us